Interim reports /

Review Panel on New Drug Regulation : final report.
Published: (1977)

"A plan for action".
Published: (1985)

FDA and the drug development process : how the agency ensures that drugs are safe and effective.
Published: (2002)

FDA-approved bargain drugs : generic products must meet high standards.
Published: (2003)

Las drogas baratas aprobadas por la FDA : los productos genéricos deben satisfacer altos niveles.
Published: (2004)

El proceso del desarrollo de las drogas y la FDA : cómo la agencia asegura que las drogas sean seguras y efectivas.
Published: (2002)

Protecting America's health : the FDA, business, and one hundred years of regulation /
by: Hilts, Philip J.
Published: (2004)

Man-in-the-plant : FDA's failure to regulate deceptive drug labeling : report together with separate views /
Published: (1978)

Drug regulation reform--oversight : hearing before the Subcommittee on Health and the Environment of the Committee on Interstate and Foreign Commerce, House of Representatives, Ninety-sixth Congress, second session ...
Published: (1980)

"Man-in-the-plant" revisited, a deceptive drug labeling practice continues : hearing before the Subcommittee on Oversight and Investigations of the Committee on Interstate and Foreign Committee, House of Representatives, Ninety-sixth Congress, second session, March 6, 1980.
Published: (1980)

The therapeutic nightmare ; a report on the roles of the United States Food and Drug Administration, the American Medical Association, pharmaceutical manufacturers, and others in connection with the irrational and massive use of prescription drugs the may be worthless, injurious, or even lethal.
by: Mintz, Morton
Published: (1965)

FDA's Faulty Safeguards Against Corruption : Concerns over Debarment Use and Authority.
Published: (2008)

Pills, profits, and politics /
by: Silverman, Milton, 1910-
Published: (1974)

The Food and Drug Administration's process for approving new drugs : report /
Published: (1980)

FDA drug bulletin.
Published: (1971)

FDA's generic drug enforcement and approval process : hearings before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Second Congress, first session, March 7 and June 5, 1991.
Published: (1992)

Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018 : report together with additional views (to accompany H.R. 5333) (including cost estimate of the Congressional Budget Office).
Published: (2018)

FDA regulatory affairs : a guide for prescription drugs, medical devices, and biologics /
Published: (2004)

The law of biologic medicine : hearing before the Committee on the Judiciary, United States Senate, One Hundred Eighth Congress, second session, June 23, 2004.
Published: (2004)

The law of biologic medicine : hearing before the Committee on the Judiciary, United States Senate, One Hundred Eighth Congress, second session, June 23, 2004.
Published: (2004)

By prescription only ; a report on the roles of the United States Food and Drug Administration, the American Medical Association, pharmaceutical manufacturers, and others in connection with the irrational and massive use of prescription drugs that may be worthless, injurious, or even lethal.
by: Mintz, Morton
Published: (1967)

The right to live /
by: Damerow, Ronald D., 1932-
Published: (1971)

Drug shortages : FDA's ability to respond should be strengthened : report to congressional requesters.
Published: (2011)

Regulating new drugs /
Published: (1973)

New drug development : science, business, regulatory, and intellectual property issues cited as hampering drug development efforts : report to congressional requesters /
Published: (2006)

Drug compounding, FDA has taken steps to implement compounding law, but some states and stakeholders reported challenges : report to Congressional Committees.
Published: (2016)

FDA interim index to evaluations published in the Federal register for NAS-NRC reviewed prescription drugs.
Published: (1976)

Drug safety : better data management and more inspections are needed to strengthen FDA's foreign drug inspection program : report to congressional requesters.
Published: (2008)

The adequacy of FDA to assure the safety of the nation's drug supply : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, first session, February 13, March 22, 2007.
Published: (2007)

FDA's drug approval process : up to the challenge? : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Ninth Congress, first session, on examining Food and Drug Administration's (FDA) drug approval process, focusing on FDA's drug approval process after a sponsor demonstrates that their benefits outweigh their risks for a specific population and use, and that the drug meet [as printed] meets standards for safety and efficacy, March 1, 2005.
Published: (2005)

Principal Differences Between the "Promoting Innovation and Access to Life-Saving Medicine Act" and the "Access to Life-Saving Medicine Act" Introduced in the 110th Congress.
Published: (2009)

Detailed Outline of the Promoting Innovations and Access to Life-Saving Medicine Act.
Published: (2009)

Q's and A's on the "Promoting Innovation and Access to Life-Saving Medicine Act".
Published: (2009)

Promoting Innovation and Access to Life-Saving Medicine Act.
Published: (2009)

The adequacy of FDA to assure the safety of the nation's drug supply : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, first session, February 13, March 22, 2007.
Published: (2007)

Drug lag : hearing before the Subcommittee on Natural Resources, Agriculture Research, and Environment of the Committee on Science and Technology, U.S. House of Representatives, Ninety-seventh Congress, first session, September 16, 1981.
Published: (1983)